A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

@article{Aghajanian2002API,
  title={A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.},
  author={Carol A. Aghajanian and Steven L. Soignet and Don S Dizon and Christine S. Pien and Julian Adams and Peter J. Elliott and Paul J Sabbatini and Vincent Miller and Martee L. Hensley and Sandra Pezzulli and Christina Canales and Adil I Daud and David R. Spriggs},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2002},
  volume={8 8},
  pages={
          2505-11
        }
}
PURPOSE The purpose of this study was to evaluate the toxicity and pharmacodynamic behavior of the novel proteasome inhibitor PS341 administered as a twice weekly i.v. bolus for 2 weeks, followed by a 1-week recovery period in patients with advanced solid tumor malignancies. EXPERIMENTAL DESIGN In this Phase I trial, 43 patients were treated with PS341 in doses ranging from 0.13 to 1.56 mg/m2/dose. A standard Phase I design was used. Pharmacodynamic studies were performed to access 20S… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 154 CITATIONS, ESTIMATED 55% COVERAGE

Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib

VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Bortezomib as a potential treatment for prostate cancer.

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2001
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

PS341 is active in multiple myeloma: preliminary report of a Phase I trial of the proteasome inhibitor PS341 in patients with hematologic malignancies

T. E. Stinchcombe, B. S. Mitchell, +4 authors R. Z. Orlowski
  • Proc. Am. Soc. Hematol.,
  • 2000

Proteasome inhibition enhances radiosensitivity of human pancreatic cancer cells in vitro

M. A. Houston, R. Liu, K. Abendroth, A. S. Baldwin, J. C. Cusack
  • Proc. Am. Assoc. Cancer Res.,
  • 2000
VIEW 1 EXCERPT

Proteasome inhibitorinduced apoptosis in CLL is associated with immediate disruption of mitochondrial function

J. C. Pahler, I. Niemer, L Calvert
  • Proc. Am. Soc. Hematol.,
  • 2000
VIEW 1 EXCERPT

Cisplatin induces NF- B activity through I B kinase dependent pathway

X. J. Yan, N. Rosales, C. Aghajanian, D. Spriggs
  • Proc. Am. Assoc. Cancer Res.,
  • 1999
VIEW 1 EXCERPT